News Column

BRIEF: GlobeImmune raises $7.5 million through private placement

February 13, 2014

By Alicia Wallace, Daily Camera, Boulder, Colo.



Feb. 13--GlobeImmune Inc., a Louisville-based biopharmaceutical firm developing drugs for pancreatic cancer and infectious diseases, recently completed a $7.5 million private placement, company officials announced Thursday.

GlobeImmune plans to use the placement of convertible notes and warrants for general corporate purposes, officials for the privately held company said in the announcement.

Officials for GlobeImmune could not be reached for additional comment.

GlobeImmune, which last year shelved plans for an initial public offering, has several drug programs in clinical studies including Tarmogen product candidates for chronic hepatitis B and a program for patients with thyroid cancer.

___

(c)2014 the Daily Camera (Boulder, Colo.)

Visit the Daily Camera (Boulder, Colo.) at www.dailycamera.com

Distributed by MCT Information Services


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Daily Camera (Boulder, CO)


Story Tools